Cargando…
PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
Autores principales: | Yu, Zhuo, Zhang, Peiqing, Gu, Weikuan, Jiang, Xicheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798071/ https://www.ncbi.nlm.nih.gov/pubmed/35117053 http://dx.doi.org/10.21037/tcr.2019.12.22 |
Ejemplares similares
-
What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
por: Bravaccini, Sara, et al.
Publicado: (2020) -
Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
por: Zhang, Xuexia, et al.
Publicado: (2022) -
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022) -
Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma
por: Wu, Fengying, et al.
Publicado: (2020) -
HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors
por: Yoneshima, Yasuto, et al.
Publicado: (2020)